Core Viewpoint - The acquisition of Shenzhen Huada Sanjian Qifa Technology Co., Ltd. and Hangzhou Huada Xifeng Technology Co., Ltd. by BGI Genomics is a strategic move to enhance its product offerings in the field of genomics, making it the only company globally to cover the entire chain of "long-read sequencing + spatial omics" technologies [1][2][3] Group 1: Acquisition Details - BGI Genomics announced a cash acquisition of 100% equity in both companies for approximately 366 million yuan [1] - The acquisition aims to integrate cutting-edge technologies, including Stereo-seq and CycloneSEQ, into BGI Genomics' existing product matrix [2][3] Group 2: Technological Integration - The integration of Stereo-seq and CycloneSEQ technologies will create a comprehensive technical chain that enhances BGI Genomics' competitive edge [2] - Stereo-seq technology is recognized for its international leadership in resolution and field of view, while CycloneSEQ offers unique advantages in long-read sequencing and real-time capabilities [3] Group 3: Strategic Positioning - This acquisition strengthens BGI Genomics' first-mover advantage in the AI medical field and brain-computer interface technology [4] - The company is positioned to lead in multiple cutting-edge sectors by leveraging its advanced technologies [4] Group 4: Financial Aspects - The acquisition is strategically timed to capitalize on the valuation window, allowing BGI Genomics to acquire assets at a more favorable price before they become commercially mature [5] - The estimated valuations for the acquired companies are significantly lower than comparable industry players, reducing financial pressure on BGI Genomics [5][6] Group 5: Risk Mitigation and Growth Potential - The acquisition includes performance guarantees from the sellers, providing a safety net for BGI Genomics and protecting shareholder interests [6] - The integration of new revenue streams from the acquired technologies is expected to enhance the company's overall revenue and profitability [6][7] Group 6: Industry Context - The acquisition aligns with the trend of deep mergers and acquisitions in the industry, reflecting a focus on strategic integration and value creation [7] - BGI Genomics' move serves as a model for similar industry consolidations, emphasizing the importance of building competitive barriers through comprehensive technology offerings [7]

Core Viewpoint - The acquisition of Shenzhen Huada Sanjian Qifa Technology Co., Ltd. and Hangzhou Huada Xufeng Technology Co., Ltd. by BGI Genomics is a strategic move to enhance its capabilities in the fields of spatial omics and nanopore sequencing, positioning the company as a leader in the global life sciences sector with a comprehensive product matrix covering "full-length sequencing + spatial omics" [1][2][3]. Group 1: Acquisition Details - BGI Genomics plans to acquire 100% equity of both companies for a total consideration of approximately 366 million yuan [1]. - The acquisition will allow BGI Genomics to integrate cutting-edge technologies into its operations, enhancing its product offerings and market position [2][3]. Group 2: Technological Integration - The acquisition will create a seamless technology chain combining short-read (DNBSEQ), long-read (CycloneSEQ), and spatial omics (Stereo-seq) technologies, making BGI Genomics the only company globally to cover these three advanced technologies [2][3]. - Stereo-seq technology is recognized for its international leadership in resolution and field of view, with applications in neuroscience, regenerative medicine, and tumor microenvironment analysis [2][3]. - CycloneSEQ technology offers unique advantages such as long-read, real-time sequencing, and portability, effectively addressing challenges in large genome assembly and clinical testing [2][3]. Group 3: Strategic Advantages - The acquisition strengthens BGI Genomics' first-mover advantage in the AI medical field, enhancing its "AI + gene sequencing" strategy and supporting the development of intelligent laboratory automation [4]. - The integration of these technologies will enable BGI Genomics to provide comprehensive services from library construction to sequencing and data analysis, significantly improving customer service capabilities and retention [3]. Group 4: Financial Considerations - The acquisition is strategically timed to capitalize on the valuation window during the target companies' incubation phase, allowing BGI Genomics to acquire assets at a more realistic value [5]. - The estimated equity value of Huada Sanjian is 158 million yuan, while Huada Xufeng is valued at 207.7 million yuan, both assessed using the income method [5]. - Performance guarantees from the sellers include commitments for cumulative net profits of at least 50.1 million yuan for Huada Sanjian and 82.8 million yuan for Huada Xufeng over specified periods, with cash compensation provisions in case of unmet targets [6]. Group 5: Market Impact - The acquisition is expected to significantly enhance BGI Genomics' revenue scale and profitability, leveraging its global sales network to promote the new technologies [6]. - The integration of new revenue streams from spatial omics and nanopore sequencing will contribute to the company's long-term growth and industry influence [6]. - The transaction aligns with the broader trend of deep mergers and acquisitions in the industry, reflecting a focus on strategic integration and value creation [6].

从交易定价合理性来看，此次收购也属于华大智造在前沿核心技术领域"低成本高价值"的精准布局。相 较行业内同类机构融资对价，交易定价更精准匹配标的实际业务价值，华大智造以更经济的投入实现核 心资产整合，降低了外延式扩张成本。此外，两家标的公司分别作出业绩承诺，并配套现金补偿及减值 补偿机制，交割前亏损由卖方现金补足、收益归华大智造，进一步锁定风险敞口，最大限度保障了投资 者的利益。 在前沿赛道布局上，此次收购进一步强化了华大智造的先发优势。AI医疗领域，华大智造"AI+基因测 序"布局已处于行业领先水平。通过持续升级实验室智能自动化(GLI)业务、加速AI驱动软件工具开发， 为智能生态筑牢底层支撑；脑机接口领域，此次纳入的时空组学Stereo-seq技术，可提供厘米级全景视 场与纳米级分辨率的精准导航，为植入式脑机接口技术突破奠定核心基础。 市场人士认为，此次收购是华大智造外延式扩张极具性价比的关键落子，既以高性价比拿下核心资产， 又凭借全球唯一的技术链条构筑起坚固护城河。在技术链唯一性与领先性双优势加持下，公司长期盈利 能力与行业话语权将进一步提升。 2月1日，华大智造(688114.SH)发布公告称，拟以合计 ...

Core Insights - The company BGI Genomics (688114.SH) announced plans to acquire 100% equity of Shenzhen Huada Sanjian Qifa Technology Co., Ltd. and Hangzhou Huada Xufeng Technology Co., Ltd. for a total of 366 million yuan, integrating key assets in spatial omics and nanopore sequencing [1] - This acquisition strengthens BGI Genomics' position in the global gene sequencing market by consolidating its strategic bases in "AI + life sciences + brain-computer interfaces," enhancing its competitive edge in multiple cutting-edge sectors [1][3] Technology Advancements - The long-read sequencing technology (CycloneSEQ) has achieved industry-leading levels in single-chip throughput and methylation direct measurement, comparable to international leader ONT, while the spatial omics technology (Stereo-seq) significantly outperforms similar products from 10X Genomics in capture area, resolution, and multi-level analysis capabilities [2] - Post-acquisition, BGI Genomics will become the only life sciences company globally to cover the entire product matrix of "full-length sequencing + spatial omics," positioning itself as a Chinese version of "Illumina + ONT + 10X Genomics" [2] Strategic Positioning - The acquisition enhances BGI Genomics' first-mover advantage in the cutting-edge sector, particularly in AI healthcare, where its "AI + gene sequencing" strategy is already industry-leading [3] - The integration of Stereo-seq technology provides precise navigation for implantable brain-computer interface technologies, establishing a core foundation for breakthroughs in this field [3] - Market analysts view this acquisition as a cost-effective expansion strategy, allowing the company to secure core assets while building a robust technological moat through unique and leading-edge technology chains [3]

Core Viewpoint - The company BGI Genomics (华大智造) announced a cash acquisition of 100% equity in Shenzhen Sanjian Qifa Technology Co., Ltd. and Hangzhou BGI Xifeng Technology Co., Ltd., focusing on advanced technologies in spatial omics and nanopore sequencing [1][2] Group 1: Acquisition Details - The total transaction price for the acquisition is set at 36,570 million yuan, with Sanjian Qifa valued at 15,800 million yuan and BGI Xifeng at 20,770 million yuan [1] - Following the acquisition, the company plans to inject additional capital of 7,000 million yuan into Sanjian Qifa and 6,000 million yuan into BGI Xifeng [1] Group 2: Strategic Implications - The acquisition will provide the company with control over two cutting-edge technology platforms, enhancing its competitive edge and profitability in the long term [1] - Sanjian Qifa and BGI Xifeng are expected to achieve profitability by 2026 and 2028, respectively, marking a significant step in the company's strategic layout [2] - This move is aimed at improving the company's technological ecosystem and boosting its independent innovation capabilities in the gene sequencing field [2]

Core Viewpoint - BGI Genomics (688114.SH) announced plans to acquire 100% equity of Shenzhen BGI Sanjian Qifa Technology Co., Ltd. and Hangzhou BGI Xufeng Technology Co., Ltd. for a total of 366 million yuan, enhancing its core technology layout and solidifying its position as a global leader in gene sequencing [1] Group 1: Acquisition Details - The acquisition aims to integrate two core assets: spatiotemporal omics and nanopore sequencing, marking a significant step in BGI Genomics' strategic development [1] - This move establishes a unique technological barrier in the upstream life sciences sector, combining short-read, long-read, and spatial omics technologies into a comprehensive product matrix [1][2] Group 2: Technological Advancements - The long-read technology (CycloneSEQ) has achieved industry-leading levels in terms of single-chip throughput and methylation direct measurement, comparable to international leader ONT [2] - The spatiotemporal omics technology (Stereo-seq) significantly outperforms similar products from 10X Genomics in terms of capture area, resolution, and multi-level analysis capabilities [2] Group 3: Financial Aspects - The acquisition is characterized as a "low-cost, high-value" strategic move, with pricing accurately reflecting the actual business value of the target companies [2] - Performance commitments from the target companies, along with cash compensation and impairment compensation mechanisms, are in place to mitigate risks and protect investor interests [2] Group 4: Strategic Positioning - This acquisition strengthens BGI Genomics' first-mover advantage in the AI healthcare sector, where it has already established a leading position with its "AI + gene sequencing" strategy [3] - The integration of Stereo-seq technology provides precise navigation capabilities essential for breakthroughs in implantable brain-computer interface technology [3] - Market analysts view this acquisition as a cost-effective expansion strategy that enhances the company's long-term profitability and industry influence through a unique technological chain [3]

南财智讯2月1日电，华大智造公告，公司于2026年1月31日召开第二届董事会第十九次会议，审议通过 《关于部分募投项目结项节余资金永久补流及部分募集资金专户销户的议案》，同意将募投项目"华大 智造研发中心项目"予以结项，该项目已达到预定可使用状态；节余募集资金金额为15768.23万元（含 利息收入及理财收益净额，实际金额以资金转出当日银行结息后余额为准），拟用于永久补充公司流动 资金；节余资金转出后，公司将注销招商银行股份有限公司深圳盐田支行、招商银行武汉未来科技城支 行相关募集资金专户。 ...

本报告依据中国资产评估准则编制 杭州华大序风科技有限公司拟收购资产 所涉及的深圳华大生命科学研究院等 6家单位持有的单分子测序相关的专利权、 技术秘密、软件著作权、作品著作权、 集成电路布图设计及商标所有权 资产评估报告 沃克森评报字(2026)第0053号 (共一册 第一册) 中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 1111020051202600181 | | --- | --- | | 合同编号: | 沃克森国际评合同字【2025】第1774号 | | 报告类型: | 非法定评估业务资产评估报告 | | 报告文号: | 沃克森评报字(2026)第0053号 | | 报告名称: | 杭州华大序风科技有限公司拟收购资产 所涉及的深圳华大生命科 学研究院等 6家单位持有的单分子测序相关的专利权、 技术秘 | | | 密、软件著作权、作品著作权、集成电路布图设计及商标所有权 | | 评估结论: | 56,174,449.23元 | | 评估报告日 : | 2025年09月30日 | | 评估机构名称: | 沃克森(北京)国际资产评估有限公司 | | 签名人员: | 施苏华 (资产评估师) ...

沃克森（北京）国际资产评估有限公司 本报告依据中国资产评估准则编制 深圳华大智造科技股份有限公司拟收购 杭州华大序风科技有限公司股权涉及的 杭州华大序风科技有限公司 股东全部权益 资产评估报告 沃克森评报字(2026)第0062号 (共一册 第一册) 二〇二六年一月三十日 中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 1111020051202600179 | | | --- | --- | --- | | 合同编号: | 沃克森国际评合同字【2025】第1772 号 | | | 报告类型: | 非法定评估业务资产评估报告 | | | 报告文号: | 沃克森评报字(2026)第0062号 | | | 报告名称: | 深圳华大智造科技股份有限公司拟收购 杭州华大序风科技有限公 司股权涉及的杭州华大序风科技有限公司股东全部权益 | | | 评估结论: | 207,700,000.00元 | | | 评估报告日: | 2026年01月30日 | | | 评估机构名称: | 沃克森(北京)国际资产评估有限公司 | | | 签名人员: | 施苏华 (资产评估师) 正式会员 编号: 47190027 | ...

深圳华大三箭齐发科技有限责任公司 审计报告 天 职 业 字 [2025]45427 号 一、审计意见 我们接受深圳华大智造科技股份有限公司(以下简称"贵公司")委托,对深圳华大三 箭齐发科技有限责任公司（以下简称"三箭齐发"）基于附注二、财务报表的编制基础编制 的财务报表进行审计,包括 2025 年 10 月 31 日、2024 年 12 月 31 日的资产负债表，2025 年１月１日-2025 年 10 月 31 日、2024 年 4 月 1 日-2024 年 12 月 31 日的利润表以及相关财 务报表附注。 目 录 审计报告- -1 2024年4月1日-2025年10月31日财务报表- -4 2024 年 4 月 1 日-2025 年 10 月 31 日财务报表附注– _7 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mo.f.gov.cn）" 进行查测 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mo.f.gov.cn） "进行查测 ： 报 审计报告 天职业字[2025]45427 号 深圳华大智造科技股份有限公司: 我们认为,后 ...